unknown
Stage
1
Investors
About
ZZ Biotech develops genetically engineered therapeutic proteins, including 3K3A-APC, a variant of human activated protein C optimized for human therapeutic use, with a focus on advancing wound therapies through licensing agreements with biotechnology companies.
Explore ZZ Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.